Pulmonary arterial hypertension (PAH) is a progressive disease leading to obstruction of the small pulmonary arteries. Currently, there are eight approved medications for PAH. This review article focuses on the mechanisms, clinical trials, efficacy, and safety profiles of each of the PAH medications. In addition, this review addresses combination PAH therapy, patient preference, and future therapies.
机构:
Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Ctr Pulm Vasc Dis, Durham, NC 27710 USADuke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Ctr Pulm Vasc Dis, Durham, NC 27710 USA